Profound Medical reported revenue of $2.48M and net income of -$10.49M for the quarter ended Jun 2026, up 12.3% year over year. This income statement covers 17 quarters of results from Dec 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2018 | Jan2019 | Dec2019 | Dec2020 | Dec2021 | Dec2022 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||
| Revenue | 1.44M | 2.23M | 2.83M | 4.18M | 2.62M | 2.21M | 5.29M | 5.98M | 5.34M | 2.48M | |||||||
| Cost of RevenueCost of Rev | 0.57M | 0.81M | 1.04M | 1.21M | 0.77M | 0.59M | 1.36M | 1.99M | 1.50M | 0.54M | |||||||
| Gross Profit | 0.87M | 1.42M | 1.79M | 2.96M | 1.85M | 1.62M | 3.93M | 3.99M | 3.83M | 1.95M | |||||||
| Operating items | |||||||||||||||||
| Research & DevelopmentR&D | 3.94M | 4.21M | 4.17M | 4.65M | 4.81M | 6.10M | 5.42M | 4.27M | 5.26M | 5.65M | |||||||
| Selling, General & AdministrativeSG&A | 4.80M | 5.06M | 6.62M | 6.66M | 8.21M | 9.33M | 7.43M | 7.09M | 6.59M | 7.36M | |||||||
| Operating ExpensesOpex | 8.74M | 9.26M | 10.79M | 11.31M | 13.02M | 15.42M | 12.84M | 11.36M | 11.85M | 13.01M | |||||||
| Operating IncomeOp. Inc | -7.88M | -7.84M | -9.00M | -8.35M | -11.17M | -13.81M | -8.91M | -7.37M | -8.02M | -11.07M | |||||||
| EBIT | -7.88M | -7.84M | -9.00M | -8.35M | -11.17M | -13.81M | -8.91M | -7.37M | -8.02M | -11.07M | |||||||
| Non-operating items | |||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.46M | 0.42M | 0.22M | 0.33M | 0.45M | 0.34M | 0.12M | 0.16M | 0.38M | 0.34M | |||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.87M | 0.52M | -0.41M | 2.83M | 0.04M | -2.17M | 0.94M | -0.94M | 0.62M | 1.25M | |||||||
| Non Operating IncomeNon Op. Inc. | 1.33M | 0.94M | -0.19M | 3.16M | 0.48M | -1.82M | 1.06M | -0.78M | 0.99M | 1.58M | |||||||
| Net income details | |||||||||||||||||
| EBT | -6.54M | -6.90M | -9.19M | -5.65M | -10.68M | -15.63M | -7.86M | -9.20M | -7.03M | -9.48M | |||||||
| Tax ProvisionsTaxes | 0.04M | 0.02M | 0.18M | -4.41M | 0.04M | 0.08M | 0.12M | -6.57M | 0.03M | 0.07M | |||||||
| Profit After TaxPAT | -6.58M | -6.92M | -9.37M | -6.92M | -10.72M | -15.70M | -8.79M | -8.18M | -7.05M | -10.49M | |||||||
| Income from Continuing OperationsIncome (Continuing) | -6.58M | -6.92M | -9.37M | -1.24M | -10.72M | -15.71M | -7.98M | -2.63M | -7.05M | -9.55M | |||||||
| Consolidated Net IncomeConsol Net Inc. | -6.58M | -6.92M | -9.37M | -1.24M | -10.72M | -15.71M | -7.98M | -2.63M | -7.05M | -9.55M | |||||||
| Income towards Parent CompanyParent Net Inc | -6.58M | -6.92M | -9.37M | -1.24M | -10.72M | -15.71M | -7.98M | -2.63M | -7.05M | -9.55M | |||||||
| Net Income towards Common StockholdersNet Income | -6.58M | -6.92M | -9.37M | 50.69M | 10.72M | -15.70M | -7.98M | 76.97M | 7.05M | -9.54M | |||||||
| Additional items | |||||||||||||||||
| EPS (Basic) | -0.27 | -0.28 | -0.38 | 2.05 | 0.36 | -0.52 | -0.26 | 2.55 | 0.19 | -0.26 | |||||||
| EPS (Diluted) | -0.27 | -0.28 | -0.38 | 2.05 | 0.36 | -0.52 | -0.26 | 2.55 | 0.19 | -0.26 | |||||||
| Shares Outstanding | 10.04M | 10.04M | 11.10M | 17.29M | 20.46M | 20.83M | 21.18M | 24.30M | 24.44M | 24.53M | 24.77M | 30.04M | 30.05M | 30.10M | 30.23M | 36.30M | 36.35M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 21.18M | 24.30M | 24.44M | 24.53M | 24.77M | 30.04M | 30.05M | 30.10M | 30.23M | 36.30M | 36.35M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 10.81M | 11.85M | 20.21M | 20.78M | 20.88M | 21.37M | 24.30M | 24.44M | 24.53M | 24.77M | 30.05M | 30.05M | 30.19M | 30.23M | 36.34M | 36.53M | |
| EBITDA | -7.88M | -7.84M | -9.00M | -8.35M | -11.17M | -13.81M | -8.91M | -7.37M | -8.02M | -11.07M | |||||||
| Tax Rate | -0.61% | -0.28% | -1.93% | 77.99% | -0.38% | -0.50% | -1.54% | 71.45% | -0.38% | -0.72% |